Why Is MODY Misdiagnosed as Type 1 or Type 2 Diabetes?
At a Glance
MODY is often misdiagnosed because it can begin in young, lean people like Type 1 diabetes, yet develop gradually without immediate insulin like Type 2. Family history, C-peptide and autoantibody results, and genetic testing can clarify the diagnosis.
In this answer
3 sections
Maturity-Onset Diabetes of the Young (MODY) is frequently misdiagnosed as Type 1 or Type 2 diabetes because it shares clinical features with both, but is much less common. While diabetes itself is diagnosed using blood glucose levels, doctors historically relied heavily on a patient’s age and weight to classify the type of diabetes [1]. Because a young age of onset mimics Type 1 diabetes [2], and a gradual onset without the immediate need for insulin mimics Type 2 diabetes [3], the rare genetic cause of MODY is often overlooked in favor of the more common types [4].
The Trap of Overlapping Symptoms
When a patient presents with elevated blood sugar, clinicians look for clues to determine the type of diabetes. Unfortunately, MODY’s features blur the lines between Type 1 and Type 2, making a clinical diagnosis challenging [5].
How MODY Mimics Type 1 Diabetes:
- Young age at diagnosis: MODY typically develops in childhood, adolescence, or early adulthood [6]. Because Type 1 diabetes is the most common form in young people, doctors often suspect Type 1 first [7].
- Lean body type: Many people with MODY are not overweight, which is a classic characteristic expected in Type 1 diabetes [7].
How MODY Mimics Type 2 Diabetes:
- Preserved insulin production: Unlike Type 1 diabetes, where the immune system destroys insulin-producing cells, people with MODY continue to make their own insulin [8]. This is often measured using a C-peptide test, which must be carefully interpreted alongside your blood glucose level at the time of the test [9].
- Gradual onset: Many people with MODY do not require insulin when first diagnosed, leading doctors to assume it must be early-stage Type 2 diabetes [3].
- Lack of DKA: MODY rarely presents with diabetic ketoacidosis (DKA), a dangerous buildup of blood acids that is common at the onset of Type 1 diabetes [3].
The Role of Age and Weight in Classification
For decades, age and body weight heavily influenced how diabetes was classified. The classic assumption was: young and thin meant Type 1; older and overweight meant Type 2.
Today, we know these rules are imperfect, but they still heavily influence clinical practice. While classic MODY patients are lean, obesity can easily coexist with a MODY-associated genetic variant [10]. If a young person with MODY happens to be overweight, a doctor may immediately label them with Type 2 diabetes [7]. In fact, one study found that applying strict traditional criteria—such as requiring a normal Body Mass Index (BMI) and no insulin treatment—missed more than 86% of genetically confirmed MODY cases in a referral center [1].
The Awareness Gap and Why Genetics Matter
Most people first seek help for diabetes symptoms from a primary care clinician. Because MODY accounts for a very small percentage of all diabetes cases, a general practitioner may rarely see a case. Studies show that limited provider awareness and a lack of education about monogenic diabetes are primary causes of diagnostic delays [11]. Furthermore, genetic testing is not a routine part of standard diabetes care. Barriers like high out-of-pocket costs, limited access to specialists, and insurance hurdles can prevent clinicians from ordering the precise tests needed to confirm MODY [12].
A misdiagnosis is frustrating and can lead to an inappropriate treatment plan. MODY is not a single condition, but a group of different genetic subtypes. Identifying your specific subtype through genetic testing is crucial because it dictates your treatment [2]. For example, some people with the HNF1A-MODY subtype are incorrectly treated with insulin for Type 1 diabetes, experiencing unstable blood sugars, when they might achieve better control with a targeted oral medication like a sulfonylurea [13][14]. Conversely, people with GCK-MODY often need no medication at all, while other subtypes may still require insulin.
Important Safety Warning: Never stop taking insulin or reduce any diabetes medication without direct supervision from your healthcare team. DKA and severe high blood sugars are life-threatening emergencies. If you suspect you have MODY, ask your doctor about diagnostic testing (such as autoantibody and C-peptide tests) and a referral to a genetic counselor or endocrinologist to safely guide your care.
Common questions in this guide
Why can MODY look like Type 1 diabetes?
Why can MODY be mistaken for Type 2 diabetes?
What tests can help tell MODY apart from Type 1 or Type 2 diabetes?
Does a family history make MODY more likely?
Would a MODY diagnosis change my diabetes treatment?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my age at diagnosis and my family history, could my diabetes be monogenic rather than Type 1 or Type 2?
- 2.Have we ever checked my C-peptide levels alongside my blood glucose, or run a diabetes autoantibody panel to help classify my diabetes type?
- 3.Are you comfortable ordering and interpreting genetic panels for MODY, or should I be referred to an endocrinologist or genetic counselor?
- 4.If genetic testing confirms a specific subtype of MODY, how would that change my current treatment and monitoring plan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
MODY Is Prevalent in Later-Onset Diabetes and Has Potential for Targeted Therapy but Is Challenging to Identify.
Sharp LN, Mirshahi UL, Colclough K, et al.
Diabetes 2026; (75(2)):361-368 doi:10.2337/db25-0545.
PMID: 41288518 - 2
Undiagnosed MODY: Time for Action.
Kleinberger JW, Pollin TI
Current diabetes reports 2015; (15(12)):110 doi:10.1007/s11892-015-0681-7.
PMID: 26458381 - 3
Gliclazide Challenge Testing as an Alternative Diagnostic Tool for Hepatocyte Nuclear Factor-1-Alpha Maturity Onset Diabetes of the Young.
Pandya S, Khairati R, Mann J, et al.
European journal of case reports in internal medicine 2025; (12(12)):005892 doi:10.12890/2025_005892.
PMID: 41377795 - 4
How do I diagnose Maturity Onset Diabetes of the Young in my patients?
Colclough K, Patel K
Clinical endocrinology 2022; (97(4)):436-447 doi:10.1111/cen.14744.
PMID: 35445424 - 5
Maturity-onset diabetes of the young (MODY) - in search of ideal diagnostic criteria and precise treatment.
Zečević K, Volčanšek Š, Katsiki N, et al.
Progress in cardiovascular diseases 2024; (85()):14-25 doi:10.1016/j.pcad.2024.03.004.
PMID: 38513726 - 6
Monogenic Defects of Beta Cell Function: From Clinical Suspicion to Genetic Diagnosis and Management of Rare Types of Diabetes.
Serbis A, Kantza E, Siomou E, et al.
International journal of molecular sciences 2024; (25(19)) doi:10.3390/ijms251910501.
PMID: 39408828 - 7
Divergent phenotypes in siblings with identical novel mutations in the HNF-1α gene leading to maturity onset diabetes of the young type 3.
Knebel B, Mack S, Haas J, et al.
BMC medical genetics 2016; (17(1)):36 doi:10.1186/s12881-016-0297-z.
PMID: 27142837 - 8
[Maturity-onset diabetes of the young].
van der Tuin K, Hannema SE, Houdijk EC, et al.
Nederlands tijdschrift voor geneeskunde 2015; (159()):A9247.
PMID: 26374728 - 9
A Clinical Prediction Model to Distinguish Maturity-Onset Diabetes of the Young From Type 1 and Type 2 Diabetes in the Chinese Population.
Fu J, Ping F, Wang T, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(8)):776-782 doi:10.1016/j.eprac.2021.05.002.
PMID: 33991656 - 10
Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.
Bai H, Yu J, Wang T, et al.
Frontiers in endocrinology 2026; (17()):1826357 doi:10.3389/fendo.2026.1826357.
PMID: 42137361 - 11
Patient perspectives on the diagnostic journey to a monogenic diabetes diagnosis: Barriers and facilitators.
Guan Y, Maloney KA, Pollin TI
Journal of genetic counseling 2020; (29(6)):1106-1113 doi:10.1002/jgc4.1247.
PMID: 32162750 - 12
The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing.
GoodSmith MS, Skandari MR, Huang ES, Naylor RN
Diabetes care 2019; (42(12)):2247-2255 doi:10.2337/dc19-0486.
PMID: 31558549 - 13
Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
Schnedl WJ, Holasek SJ, Schenk M, et al.
Wiener klinische Wochenschrift 2021; (133(5-6)):241-244 doi:10.1007/s00508-020-01770-2.
PMID: 33245425 - 14
Maturity-onset diabetes of the young (MODY): an update.
Anık A, Çatlı G, Abacı A, Böber E
Journal of pediatric endocrinology & metabolism : JPEM 2015; (28(3-4)):251-63.
PMID: 25581748
This page is for informational purposes only and does not constitute medical advice. Do not stop insulin or change diabetes treatment without your healthcare team's guidance; ask whether MODY testing or specialist referral is appropriate.
Get notified when new evidence is published on MODY.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.